Multiple Dose Study to Evaluate Drug-drug Interactions, Safety and Tolerability of NDC-002 in Healthy Volunteers
PHASE1CompletedINTERVENTIONAL
Enrollment
33
Participants
Timeline
Start Date
January 12, 2023
Primary Completion Date
March 15, 2023
Study Completion Date
March 15, 2023
Conditions
Stroke SequelaeStroke
Interventions
DRUG
NDC-002
Combination of NDC-002B and NDC-002C
Trial Locations (1)
Unknown
Insan Medical Foundation Metro Hospital, Anyang-si
All Listed Sponsors
lead
Dr. Noah Biotech Inc.
INDUSTRY
NCT06090474 - Multiple Dose Study to Evaluate Drug-drug Interactions, Safety and Tolerability of NDC-002 in Healthy Volunteers | Biotech Hunter | Biotech Hunter